Related Experiment Video

Updated: Mar 20, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K

Interrogating the Cancer Genome to Deliver More Precise Cancer Care

Joaquin Mateo1, Johann S de Bono1

  • 1From The Institute of Cancer Research, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 2, 2016
PubMed

Insights

Precision medicine aims to tailor cancer treatments using tumor molecular makeup for better patient outcomes. Challenges include reclassifying cancers, adapting clinical trials, and regulatory frameworks for genomic biomarkers.

Area of Science:

  • Oncology
  • Genomics
  • Translational Medicine

Background:

  • Precision medicine seeks to optimize cancer treatment selection based on individual tumor molecular profiles.
  • Identifying distinct cancer subtypes and matching them with targeted therapies is crucial for improving patient survival and quality of life.
  • Advances in next-generation sequencing (NGS) enable comprehensive cancer genome interrogation for biomarker discovery.

Purpose of the Study:

  • To review the challenges posed by the 'sequencing revolution' in precision oncology.
  • To discuss the need for reclassifying cancers based on clinically relevant biologic/phenotypic clusters.
  • To examine adaptations required in clinical trial design and regulatory approval processes for biomarker technologies and drugs.

Main Methods:

  • Review of current challenges in precision medicine implementation.
  • Discussion of the impact of next-generation sequencing on cancer research and drug development.
  • Analysis of the requirements for analytical validation and clinical qualification of DNA-based biomarkers.

Main Results:

  • The sequencing revolution necessitates reclassification of cancers into biologically distinct subtypes.
  • Clinical trial methodologies must adapt to evaluate targeted therapies based on genomic biomarkers.
  • Regulatory frameworks need adjustment for the approval of novel biomarker technologies and associated drugs.

Conclusions:

  • Successful implementation of precision medicine requires addressing challenges in cancer classification, clinical trials, and regulatory pathways.
  • Ensuring the safe integration of genomic biomarkers into routine clinical practice is paramount.
  • The ultimate goal is to leverage molecular insights from cancer genomics to improve patient outcomes.

More Related Videos

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

20.0K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.4K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.4K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.2K